Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268055 | 0.90 | ATM (0.54) | CASRATML3MBTL1ALDH1A1GAA | |
| SCHEMBL5266579 | 0.89 | L3MBTL1 (0.50) | CASRATML3MBTL1P2RX7ALDH1A1 | |
| SCHEMBL5269709 | 0.88 | L3MBTL1 (0.52) | CASRATML3MBTL1P2RX7ALDH1A1 | |
| SCHEMBL7194585 | 0.86 | CASR (0.48) | CASRATML3MBTL1P2RX7ALDH1A1 | |
| SCHEMBL5270712 | 0.85 | CASR (0.54) | CASRATML3MBTL1P2RX7ALDH1A1 | |
| SCHEMBL5265964 | 0.80 | SLC6A2 (0.49) | CASRATML3MBTL1ALDH1A1GAA | |
| SCHEMBL5270843 | 0.80 | SLC6A2 (0.49) | CASRATML3MBTL1ALDH1A1GAA | |
| SCHEMBL5266007 | 0.79 | KMT2A (0.50) | CASRATML3MBTL1ALDH1A1GAA | |
| SCHEMBL5273002 | 0.78 | LMNA (0.43) | CASRALDH1A1LMNAPOLB | |
| SCHEMBL5266903 | 0.78 | L3MBTL1 (0.56) | CASRATML3MBTL1P2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1074539-B1 | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL CO (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-6894190-B2 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-17 | — | — | US | disclosed |
| US-20030232886-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-6403832-B1 | MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1074539-A2 | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232886-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | ALDH1A2, CYP8B1, CYP11B2 | CASR 2902/4885ATM 4581/4885L3MBTL1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.